Want to see CABA full AI Analyst Report?
Top Page
Cabaletta Bio
(NASDAQ:CABA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-37.89% Downside)
Action:Reiterated
Date:09/29/26
The score is held down primarily by weak financial performance (no revenue, expanding losses, and heavy cash burn) and bearish technicals (below major moving averages with negative MACD). A meaningful offset is the positive corporate event—a substantial cash infusion from warrant exercises—supporting balance-sheet flexibility, while valuation remains difficult to assess due to negative earnings and no dividend.
Positive Factors
Low leverage and stronger equity base
Relatively low leverage and a sharply higher equity base provide greater solvency and financial flexibility than a highly debt-funded structure. This can help Cabaletta sustain development activity and absorb operating volatility while its clinical programs remain pre-commercial.
Negative Factors
No commercial revenue or approved products
The absence of approved products and recurring sales means Cabaletta currently has no established commercial revenue engine. Its ability to create durable value therefore depends on successful clinical development, regulatory progress, and eventual product launches that remain uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and stronger equity base
Relatively low leverage and a sharply higher equity base provide greater solvency and financial flexibility than a highly debt-funded structure. This can help Cabaletta sustain development activity and absorb operating volatility while its clinical programs remain pre-commercial.
Read all positive factors
Cabaletta Bio (CABA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$327.22M
Dividend YieldN/A
Average Volume (3M)5.69M
Price to Earnings (P/E)―
Beta (1Y)3.96
Revenue GrowthN/A
EPS Growth41.56%
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.58
Shares Outstanding169,545,440
10 Day Avg. Volume5,262,718
30 Day Avg. Volume5,692,168
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$14.67Price Target Upside355.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.36
Revenue Forecast (FY)N/A
Cabaletta Bio Business Overview & Revenue Model
Company Description
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicate...
How the Company Makes Money
Cabaletta Bio does not have approved products and therefore does not generate recurring product sales revenue. Its funding and reported revenue, when present, are primarily derived from collaboration and licensing-related arrangements (e.g., upfro...
Cabaletta Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -177.63M | -164.21M | -113.41M | -66.25M | -51.80M | -45.56M |
| Net Income | -181.32M | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
Balance Sheet | ||||||
| Total Assets | 256.73M | 165.08M | 185.05M | 253.65M | 116.97M | 126.34M |
| Cash, Cash Equivalents and Short-Term Investments | 225.10M | 133.60M | 163.96M | 241.25M | 106.55M | 122.22M |
| Total Debt | 25.71M | 27.10M | 15.60M | 5.02M | 5.14M | 0.00 |
| Total Liabilities | 46.13M | 53.03M | 32.71M | 17.45M | 12.45M | 8.38M |
| Stockholders Equity | 210.59M | 112.05M | 152.34M | 236.20M | 104.52M | 117.96M |
Cash Flow | ||||||
| Free Cash Flow | -154.21M | -132.31M | -90.43M | -54.24M | -48.83M | -35.27M |
| Operating Cash Flow | -153.93M | -131.08M | -88.22M | -53.55M | -46.38M | -34.11M |
| Investing Cash Flow | 50.67M | -50.27M | 47.29M | -22.45M | -27.22M | 6.00M |
| Financing Cash Flow | 182.78M | 100.35M | 11.68M | 187.63M | 32.98M | 48.90M |
Cabaletta Bio Technical Analysis
Negative
3.22
Price Trends
2.69
Negative
2.89
Negative
2.90
Negative
Market Momentum
-0.25
Positive
31.61
Neutral
37.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CABA, the sentiment is Negative. The current price of 3.22 is above the 20-day moving average (MA) of 2.21, above the 50-day MA of 2.69, and above the 200-day MA of 2.90, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 31.61 is Neutral, neither overbought nor oversold. The STOCH value of 37.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CABA.
Cabaletta Bio Risk Analysis
Cabaletta Bio disclosed 23 risk factors in its most recent earnings report. Cabaletta Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Risks Related to Stock Price Volatility Q2, 2026
2.
Risks Related to Not Paying Dividends Q2, 2026
3.
Risks Related to Raising Additional Capital Q2, 2026
Cabaletta Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $413.05M | -2.47 | -64.25% | ― | ― | -29.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $125.20M | -0.55 | -68.99% | ― | 196.02% | 98.71% | |
49 Neutral | $327.22M | -1.22 | -128.27% | ― | ― | 41.56% | |
49 Neutral | $220.77M | -1.42 | -57.61% | ― | -94.10% | -122.58% | |
48 Neutral | $105.14M | -2.45 | -38.80% | ― | -100.00% | -392.92% | |
40 Underperform | $49.34M | -0.42 | -89.11% | ― | 10.02% | 39.66% |
* Healthcare Sector Average
CABA
Cabaletta Bio
1.93
-0.56
-22.49%
TNXP
Tonix Pharma
7.30
-12.76
-63.61%
BDTX
Black Diamond Therapeutics
1.83
-1.97
-51.84%
AVIR
Atea Pharmaceuticals
5.15
2.04
65.59%
CRBU
Caribou Biosciences
0.46
-1.92
-80.67%
TRDA
Entrada Therapeutics Inc
5.67
-0.14
-2.41%
Cabaletta Bio Corporate Events
Financial DisclosuresPrivate Placements and Financing
Cabaletta Bio Boosts Cash Through Warrant Exercises
Positive
Sep 14, 2026
Cabaletta Bio, a biotechnology company developing engineered immune cell therapies for autoimmune and other serious diseases, continues to focus on patients with high unmet medical needs, reinforcing its position in the emerging cell therapy marke...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.